Abstract: A corrosion-resistant granular magnetic recording medium with improved recording performance comprises a non-magnetic substrate having a surface; and a layer stack on the substrate surface, including, in order from the surface: a granular magnetic recording layer; an intermediate magnetic de-coupling layer; and a corrosion preventing magnetic cap layer. The intermediate magnetic de-coupling layer has an optimal thickness and/or composition for: (1) promoting magnetic exchange de-coupling between the granular magnetic recording layer and the magnetic cap layer; and (2) reducing the dynamic closure field (Hcl) for determining writeability and eraseability of the medium. Grain boundaries of the magnetic cap layer are substantially oxide-free, and have a greater density and lower average porosity and surface roughness than those of the granular magnetic recording layer.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to anti IL13 antibodies that hind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: A corrosion-resistant granular magnetic recording medium with improved recording performance comprises a non-magnetic substrate having a surface; and a layer stack on the substrate surface, including, in order from the surface: a granular magnetic recording layer; an intermediate magnetic de-coupling layer; and a corrosion preventing magnetic cap layer. The intermediate magnetic de-coupling layer has an optimal thickness and/or composition for: (1) promoting magnetic exchange de-coupling between the granular magnetic recording layer and the magnetic cap layer; and (2) reducing the dynamic closure field (Hcl) for determining writeability and eraseability of the medium. Grain boundaries of the magnetic cap layer are substantially oxide-free, and have a greater density and lower average porosity and surface roughness than those of the granular magnetic recording layer.

Abstract: A corrosion-resistant granular magnetic recording medium with improved recording performance comprises a non-magnetic substrate having a surface; and a layer stack on the substrate surface, including, in order from the surface: a granular magnetic recording layer; an intermediate magnetic de-coupling layer; and a corrosion preventing magnetic cap layer. The intermediate magnetic de-coupling layer has an optimal thickness and/or composition for: (1) promoting magnetic exchange de-coupling between the granular magnetic recording layer and the magnetic cap layer; and (2) reducing the dynamic closure field (Hcl) for determining writeability and eraseability of the medium. Grain boundaries of the magnetic cap layer are substantially oxide-free, and have a greater density and lower average porosity and surface roughness than those of the granular magnetic recording layer.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: A corrosion-resistant granular magnetic recording medium with improved recording performance comprises a non-magnetic substrate having a surface; and a layer stack on the substrate surface, including, in order from the surface: a granular magnetic recording layer; an intermediate magnetic de-coupling layer; and a corrosion preventing magnetic cap layer. The intermediate magnetic de-coupling layer has an optimal thickness and/or composition for: (1) promoting magnetic exchange de-coupling between the granular magnetic recording layer and the magnetic cap layer; and (2) reducing the dynamic closure field (Hcl) for determining writeability and eraseability of the medium. Grain boundaries of the magnetic cap layer are substantially oxide-free, and have a greater density and lower average porosity and surface roughness than those of the granular magnetic recording layer.